This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=99 http://www.lsis.com/goto/r99/rss 2012-02-05T11:11:03+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 The present work details the development of a core-shell model for the purposes of obtaining potential-derived point charges from the ab initio molecular electrostatic potential. In contrast to atomic point charge models, the core-shell model decomposes all atoms into a core with static charge located at a fixed atomic position and a shell with variable charge and position. The optimization of shell charges and positions is discussed. The core-shell model was found to significantly improve (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 MISSISSAUGA, ONTARIO-(Marketwire -02/02/12)- The Board of Directors of CML HealthCare Inc. ("CML") (TSX: CLC.TO - News) today announced that Thomas G. Wellner will join the company as Chief Executive Officer, effective February 6, 2012. Tom brings to CML a broad range of leadership experience gained from 20 years with Eli Lilly & Co. in senior roles in Canada, China, United States, Latin America and the United Kingdom. From 2004 to 2007, he was President and General Manager of Lilly (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Merck & Co. swung to a fourth-quarter profit from a year-earlier loss that was weighed down by an asset write-down for a drug-research setback, while sales inched up 2%. The Whitehouse Station, N.J., drug maker issued a forecast for full-year 2012 results that leaves room for earnings growth, while sales are expected to be flat or down due to the impending loss of U.S. patent protection for its top-selling drug, the asthma and allergy treatment Singulair. The expected generic competition for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Objective: To summarize the peer-reviewed literature on patient preferences for depression treatments and the impact of these preferences on the outcomes of treatment.Data Sources: Studies were identified via a systematic search conducted simultaneously in PsycINFO and MEDLINE using EBSCOhost and EMBASE. Publications were retrieved in March 2010.Study Selection: Search terms included depression OR MDD OR major depressive disorder, patient preference, treatment preference, intervention (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 A treatment for Alzheimer's disease is the drug industry's longest shot, and any brave investors willing to place a bet on the outcome are likely to focus on Eli Lilly & Co. Lilly and Pfizer Inc are the farthest along in developing experimental medicines for the memory-robbing disease. But Lilly, as the far smaller company, has much more upside for its share price if it hits pay dirt. The field is littered with high-profile failures, one of the most recent being a previous Lilly compound. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 SAN DIEGO-(BUSINESS WIRE)- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego. The Phase II study was completed in late 2011 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 o-Quinone forming estrogens and selective estrogen receptor modulators (SERMs) have been associated with carcinogenesis. LY2066948, a novel SERM in development by Eli Lilly for the treatment of uterine fibroids and myomas, has structural similarity to the equine estrogen equilenin present in hormone replacement formulations; both contain a naphthol group susceptible to oxidative metabolism to o-quinones. LY2066948 was synthesized and assayed for antiestrogenic activity, and in cell culture was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 We report a phase 1 study to examine the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogenic) enzastaurin in combination with single-agent temozolomide. The study was conducted in patients with recurrent glioblastoma or newly diagnosed disease that was not treatable with standard (chemo)radiotherapy. Patients were treated with standard dose temozolomide (200 mg/m(2) for 5 days every 4 weeks) together with daily oral enzastaurin. Three dose levels of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of ?-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD). Eli Lilly & Co is developing an intravenous formulation of solanezumab for the treatment of mild-to-moderate AD. Acute and subchronic treatment with solanezumab of transgenic mice attenuated or reversed memory deficits with no effects on incidence or severity of cerebral amyloid angiopathy-associated (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 The asymmetric hydrogenation of tetrasubstituted ?,?-unsaturated ketones has been accomplished using an in situ formed rhodium-Josiphos catalyst. The reaction is enhanced by addition of catalytic zinc(II) triflate, which significantly improves turnover frequency while suppressing epimerization of the products. |-| Org Lett. |-| Calvin JR, Frederick MO, Laird DL, Remacle JR, May SA. |-| Chemical Product Research and Development, and Discovery Chemistry Research and Technology, Eli Lilly and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Drug makers Pfizer Inc. and Eli Lilly & Co. were hurt by the "patent cliff," with each reporting declines in fourth-quarter profit due to new generic competition for top-selling drugs. Both companies also spoke cautiously about experimental Alzheimer's disease drugs they're developing separately, though investor enthusiasm has mounted in the off chance that one or both of the drugs will reach the market. Key clinical data for both drugs are due out later this year. Pfizer's profit declined 50% (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 The central nervous system (CNS) pharmacokinetics (PK) of drugs that have pharmacological targets in the brain are not often understood during drug development and this gap in knowledge is a limitation in providing a quantitative framework for translating nonclinical pharmacologic data to the clinical patient population. A focus of translational sciences is to improve the efficiency of clinical trial design via a more judicious selection of clinical doses based on nonclinical data. We (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 NEWBURYPORT, MA and NEW ORLEANS, LA-(Marketwire - January 31, 2012) - Informex, Booth 425 - PCI Synthesis, Inc. (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, has significantly increased its bench strength in quality control and research and development with the hiring of several experts in recent months. "We are investing significantly in the people, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Eli Lilly & Co. reported fourth- quarter profit that beat analysts estimates as higher sales of its depression and diabetes medicines helped to counter a 44 percent plunge in revenue from the schizophrenia drug Zyprexa. Net income fell 27 percent to $858.2 million, or 77 cents a share, the Indianapolis-based company said today in a statement. Profit excluding certain items beat by 6 cents the average of 17 analyst estimates compiled by Bloomberg. Revenue from the antidepressant Cymbalta rose (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 GlaxoSmithKline Plc (GSK), Eli Lilly & Co. and Pfizer Inc. (PFE) are among about half a dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, three people with knowledge of the situation said. The owners of Mustafa Nevzat, or MN Pharmaceuticals as the Istanbul-based company is known, have hired Bank of America Merrill Lynch to advise on the stake sale, said the people, who declined to be identified because (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8106090 |-| Title: 1-amino linked compounds |-| Inventors: Blaszczak; Larry Chris (Indianapolis, IN), Pulley; Shon Roland (Noblesville, IN), Robertson; Michael Alan (Indianapolis, IN), Sheehan; Scott Martin (Carmel, IN), Shi; Qing (Carmel, IN), Wiley; Michael Robert (Zionsville, IN) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8106077 |-| Title: Compounds and methods for modulating FXR |-| Inventors: Bell; Michael Gregory (Indianapolis, IN), Doti; Robert Anthony (Indianapolis, IN), Dowling; Matthew Scott (Irvine, CA), Genin; Michael James (Zionsville, IN), Lander; Peter Ambrose (Indianapolis, IN), Ma; Tianwei (Carmel, IN), Mantlo; Nathan Bryan (Brownsburg, IN), Ochoada; Jason Matthew (Greenwood, IN), Stelzer; Lindsay Scott (Indianapolis, IN), Stites; Ryan Edward (Indianapolis, IN), Warshawsky; (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 BACKGROUND: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass grafting (CABG) surgery. The objective of this study was to determine the impact of POAF on both short- and long-term mortality following isolated CABG. HYPOTHESIS: POAF is associated with a poorer short and long-term mortality following CABG. METHODS: We retrospectively analyzed the preoperative and operative data of 6728 consecutive patients undergoing a first isolated CABG. RESULTS: The (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 "Off-label" prescribing is the use of a drug in a fashion other than one approved by the Food and Drug Administration (FDA). Some courts assume that the PDR is comprehensive enough to apply its guidelines to establish the standard of care. This assumption undermines the physician's judgment in deciding how, when and for what ailment a drug should be used. It substitutes the judgment of the PDR and FDA for the physician in assessing illness and applied pharmacology. We report the results of a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Abstract Objective: This preliminary, 32-week study assessed the safety, tolerability, and pharmacokinetics of duloxetine in pediatric patients (aged 7-17 years) with major depressive disorder. Methods: Patients received flexible duloxetine doses of 20-120?mg once daily, with dose changes made based on clinical improvement and tolerability. Pharmacokinetic samples were collected across all duloxetine doses, and data were analyzed using population modeling. Primary outcome measures (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 ABSTRACT: Study Design. Controlled animal experiments.Objective. To test the dose and efficacy of Teriparatide in a rat spinal fusion model.Summary of Background Data. Teriparatide was shown to enhance spinal fusion in rats and rabbits previously, but the dose-dependent effect of Teriparatide in spinal fusion in rats was not well characterized.Methods. A 0.5à 0.5cm trabecular bone graft was taken and implanted onto the L5 and L6 transverse processes of the same rat. Rats were randomly assigned (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Breast cancer is the most common non-cutaneous cancer diagnosed in women in the United States and the second most common cause of cancer-related mortality. Over the past two decades, the progress in screening and adjuvant systemic therapies noticeably improved the survival rate. However, traditional methods of characterizing tumors are imprecise and create heterogeneous groupings of tumors and patients. As a result, despite the important medical advances in diagnosis and treatment of breast (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 (TAMPA, FLORIDA, USA, 26 January 2012) ISPE announced today that the US FDA s Grace McNally will appear at the Society s upcoming Lessons from 483s: Enhancing Efficiency, Quality and cGMP Compliance Conference. McNally will add her expertise to that of other industry and regulatory experts at the two-day event, which will review recent regulatory citations (FDA-483s) and provide guidance on how the citations can be avoided. This conference will give pharmaceutical professionals the vital (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Jubilant Life Sciences Ltd. (530019.BY) has bought out U.S.-based Eli Lilly & Co.'s (LLY) stake in the equal joint venture formed by the two companies in 2008 to provide outsourced early-stage drug development services, its executive director for finance said Wednesday. "The joint venture, Vanthys Pharmaceuticals, will now be 100% owned by Jubilant Life," R. Sankaraiah told Dow Jones Newswires. Vanthys Pharmaceuticals, based in Bangalore, was working on taking experimental drugs from the stage (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8101760 |-| Title: Glucocorticoid receptor modulator and methods of use |-| Inventors: Carson; Matthew William (Fishers, IN), Coghlan; Michael Joseph (Fishers, IN) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8101638 |-| Title: 6-substituted nicotinamide derivatives as opioid receptor antagonists |-| Inventors: Siegel; Miles Goodman (Indianapolis, IN), Stucky; Russell Dean (Indianapolis, IN), Takeuchi; Kumiko (Indianapolis, IN) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8101761 |-| Title: (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis |-| Inventors: Carson; Matthew William (Fishers, IN), Coghlan; Michael Joseph (Fishers, IN) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Johnson & Johnson officials hid three studies showing some patients using Risperdal developed diabetes while claiming the antipsychotic drug didn t cause the disease, a witness testified. As early as 1999, Johnson & Johnson s Janssen unit had researchers findings that about half the patients taking Risperdal in a study comparing its risks to those of Eli Lilly & Co. s Zyprexa antipsychotic drug developed diabetes after a year on the medication, Joseph Glenmullen, a psychiatrist and Harvard (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 OBJECTIVE: To describe clinical fracture rates, back pain, and health-related quality of life (HRQOL) in postmenopausal women with osteoporosis who are receiving glucocorticoids (GC), during a 36-month study of teriparatide treatment for up to 18 months, with an additional 18-month followup period when patients were receiving other osteoporosis medications. METHODS: A prospective, multinational, observational study. Data for clinical fractures, back pain (by visual analog scale; VAS) and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 AIMS/HYPOTHESIS: The aim of this study was to determine whether exenatide improves haemodynamic function in patients with type 2 diabetes with congestive heart failure (CHF). METHODS: The main eligibility criteria for inclusion were: male/female (18-80 years) with type 2 diabetes and CHF (ejection fraction ?35%, and New York Heart Association functional class III or IV). Out of 237 patients screened, 20 male (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8097652 |-| Title: AMPA receptor potentiators |-| Inventors: Dominguez-Manzanares; Esteban (Madrid, ES) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders. #STR00001# text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Objective:Although several epidemiological studies have investigated associations between TNF-? and insulin resistance, results have been inconsistent. We studied the relationship between TNF-? and glucose tolerance status as part of the Insulin Resistance Atherosclerosis Study.Research Design and Methods:Serum concentrations of TNF-? were measured in 1558 individuals in a triethnic population across a spectrum of glucose tolerance. Insulin sensitivity and insulin secretion were assessed by (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Aims Antibody formation to therapeutic peptides is common. This analysis characterizes the time-course and cross-reactivity of anti-exenatide antibodies and potential effects on efficacy and safety. Materials and Methods Data from ITT patients in 12 controlled (n=2225, 12-52wks) and 5 uncontrolled (n=1538, up to 3yrs) exenatide BID trials and 4 controlled (n=653, 24-30wks) exenatide once weekly (QW) trials with 1 uncontrolled period (n=128, 52wks) were analyzed. Results Mean titers peaked (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 The U.K.'s health-care cost-effectiveness body Friday confirmed initial guidance recommending Eli Lilly & Co. (LLY) and Amylin Pharmaceuticals Inc.'s (AMLN) Type 2 diabetes drug Bydureon for use in the U.K.'s publicly funded National Health Service. In final guidance, the National Institute for Health and Clinical Excellence, or NICE, said the injectable medicine, known generically as exenatide, could be given in combination with certain other drugs in obese patients with a body mass index (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Clonally derived recombinant cell lines are highly desired to achieve consistent production of recombinant biotherapeutics. Despite repeated rounds of cloning by limiting dilution or single cell cloning, the resulting cell lines have often been observed to diverge, becoming a heterogeneous population and losing productivity over long-term sub-culturing. To understand the underlying molecular mechanisms, we developed quantitative polymerase chain reaction (qPCR) assays for the analysis of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Two separate controlled and blinded studies were conducted to confirm the dose and non-interference of spinosad and milbemycin oxime (MO) administered orally in combination or alone to dogs for the treatment and control of experimentally induced flea infestations (Ctenocephalides felis) and adult hookworm infections (Ancylostoma caninum). For each study, dogs were allocated randomly based on pre-treatment adult flea and hookworm egg counts to one of four treatment groups of 10 animals each. In (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Objective:? To examine the real-world role of tricyclic antidepressants (TCAs) in fibromyalgia (FM) treatment. Methods:? Using privately insured U.S. administrative claims data, this study examined TCA use for newly diagnosed FM patients. Patients ages 18 to 64?years with ?2 FM diagnoses (ICD-9-CM: 729.1) during Q1:2007 to Q1:2009, no previous FM diagnosis, and continuous eligibility for insurance during the year before and after the first FM diagnosis ("study period") were (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Despite the advent of new drug classes, the global epidemic of cardiometabolic disease has not abated. Continuing unmet medical needs remain a major driver for new research. Drug discovery approaches in this field have mirrored industry trends, leading to a recent increase in the number of molecules entering development. However, worrisome trends and newer hurdles are also apparent. The history of two newer drug classes-glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8093302 |-| Title: Substituted tetralins as selective estrogen receptor-.beta. agonists |-| Inventors: Thomas; Elizabeth Marie (Lexington, KY), Norman; Bryan Hurst (Indianapolis, IN), Kroin; Julian Stanley (Indianapolis, IN) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| The present invention relates to novel tetralin ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 CHICAGO, Illinois, January 9, 2012 - Only 10% of molecules that enter Phase II will reach market, according to recent analysis by the Pharmaceutical Benchmarking Forum (PBF). And that is on top of growing attrition rates in earlier phases for preclinical and initial human studies that make the overall challenge of bringing drugs through Development even greater. This analysis is based on very detailed data from the PBF - which consists of the leading pharmaceutical companies - and offers the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Johnson & Johnson will pay more than $1 billion in civil and criminal penalties to the federal government and individual states to settle an investigation into the marketing practices of its anti-psychotic drug Risperdal, Bloomberg News Service reported Thursday. The figure would be in line with what Eli Lilly & Co. paid three years ago to settle claims that it marketed a similar anti-psychotic drug, Zyprexa, for illnesses that weren t approved by the U.S. Food and Drug Administration. ÂœThese (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Eli Lilly & Co (LLY.N) forecast a steeper-than-expected decline in profit for 2012, the first full year without exclusive rights to its big-selling Zyprexa schizophrenia treatment. Shares fell 3.5 percent after Lilly announced its forecast on Thursday. The drugmaker projected earnings in the range of $3.10 per share to $3.20 per share for 2012. For 2011, Lilly said it expects to meet or exceed its profit forecast of $4.30 per share to $4.35 per share, excluding items. Including items, Lilly (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 Transmembrane AMPA receptor regulatory proteins (TARPs) are auxiliary subunits that modulate AMPA receptor trafficking, gating and pharmacology throughout the brain. Why cornichon-2 (CNIH-2), another AMPA receptor-associated protein, modulates AMPA receptor gating and pharmacology in hippocampal neurons but not cerebellar granule neurons remains unresolved. Here, we report that CNIH-2 differentially impacts Type-Ia (?-2 or ?-3) vs. Type-Ib (?-4 or ?-8) TARP-containing AMPA receptors. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 INDIANAPOLIS, IN-(Marketwire - January 04, 2012) - Harlan Laboratories Inc., a leading contract research organization and research models and services company, announced today that Doug Vaughan has been recruited as Chief Financial Officer and David Broecker will join the company as President, Research Models & Services (RMS). Both will report to Hans Thunem, CEO of Harlan Laboratories, and be a part of the Management Committee. "In spite of challenging pre-clinical markets, Harlan is (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=99 OBJECTIVES: To provide a current overview of the diagnostic work-up and management of painful diabetic polyneuropathy (PDPN). METHODS: A review covering the literature from 2004 to 2011, which describes the tools designed to diagnose neuropathic pain and assess its severity, including self-administered questionnaires, validated laboratory tests and simple handheld screening devices, and the evidence-based therapeutic approaches to PDPN. RESULTS: The clinical aspects, pathogenesis, and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Indian pharmaceutical company, Zydus Cadila is planning to withdraw from its collaboration with Eli Lilly that involved joint drug discovery for cardiovascular diseases. Both the companies entered into the drug discovery alliance in March 2009. It is believed that Zydus Cadila and Eli Lilly are faced with issues concerning differences in strategy and rising costs of research. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8088776 |-| Title: Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |-| Inventors: Aicher; Thomas Daniel (Superior, CO), Chen; Zhaogen (Shanghai, CN), Hinklin; Ronald Jay (Longmont, CO), Hite; Gary Alan (Indianapolis, IN), Krasutsky; Alexei Pavlovych (Zionsville, IN), Li; Renhua (Fishers, IN), McCowan; Jefferson Ray (Indianapolis, IN), Saeed; Ashraf (Westfield, IN), Snyder; Nancy June (Lizton, IN), Toth; James Lee (Knightstown, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8088800 |-| Title: 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |-| Inventors: Benesh; Dana Ra.epsilon. (Westfield, IN), Blanco-Pillado; Maria-Jesus (Indianapolis, IN) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| The present invention relates to compounds of formulae (I) and (II) useful as opioid receptor antagonists for the treatment of obesity, wherein p is 0, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=99 Among the ranks of large pharmaceutical companies this year, there was a clear standout: Bristol-Myers Squibb. Pfizer, Abbott Laboratories, and Eli Lilly all managed to notch share price increases of greater than 15%. So did Amgen, which continued to define the border between the biotechnology companies and big pharma, which it looks a bit more like every single year. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=99 United States Patent: 8084489 |-| Title: Glucagon receptor antagonists, preparation and therapeutic uses |-| Inventors: Chappell; Mark Donald (Noblesville, IN), Conner; Scott Eugene (Indianapolis, IN), Tripp; Allie Edward (Indianapolis, IN), Zhu; Guoxin (Shanghai, CN) |-| Assignee: Eli Lilly and Company (Indianapolis, IN) |-| The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have glucagon receptor antagonist or inverse agonist (…)